Conquer Cancer Through AI

NEWS

- Revenue of US$0.01 million for the quarter ended December 31, 2021
- Participation in "SEHA Virtual Hospital" project in Abu Dhabi, UAE, ongoing
- Placement of advances of US$1.0 million and number of advances since IPO reached a total of US$1.5 million
- 2 C-suite hires and 1 board member joined CYPN (the highest impact conference in AI field)
- Plans to increase in the MSCI World Index

1. Major Activities

C1 Cube Performance

Steep growth in 5Q of 2021 with sales reaching approximately $5m

Lunit 2021 5Q Sales Trends



(2021Q4) Lunit Detection Alliance is a "Tier 1" partnership with Lunit, a digital pathology company with approximately $6 million in revenue for 2021 (excluding advance payment revenue, Lunit expects to reach $10 million in revenue for 2021). Lunit is a global leader in medical AI with its cancer diagnostic AI solutions being used in over 30 hospitals and central labs adopting Indica Labs' digital pathology platform. Lunit's AI solutions are used for breast cancer, prostate cancer and tissue image analysis tools such as HALO, HE and IHC Multiplex Analysis and Tissue Studio. Lunit has 40 of Quantum Leaders' Pharma customers in discussions to sign agreements with various oncology clinical trials and companies. Lunit's commercialization plan CLARIS (Clinical Analytics Platform Strategy).

Lunit INSIGHT CXR adopted by global military hospitals in Korea for the advancement of public healthcare

(2021Q4) The company's new 3-sq. ft. office in Jackson, Lunit INSIGHT CXR for Chest X-Ray, Lunit's AI solution for chest X-ray, has received approval from the Ministry of Food and Drug Safety for Conformité Européenne Medical Device Regulation (CE MDR) and has been approved in Korea and CE and the National Tax Service of Korea (NTS) for use as a medical diagnostic aid. Lunit's AI solutions, in particular, are attractive and are being in demand because they are cost-effective, time-saving, and beneficial in reducing workload and contributing to the improvement of public healthcare. Lunit INSIGHT CXR for Chest X-Ray, Lunit's AI solution for chest X-ray, has received approvals, but also in other public healthcare fields.

Participation in "South Korean 2030" bids leads to $25 business expansion

(2021Q4) The company's new 3-sq. ft. office in Jackson, Lunit INSIGHT CXR for Chest X-Ray, Lunit's AI solution for chest X-ray, has received approval from the Ministry of Food and Drug Safety for Conformité Européenne Medical Device Regulation (CE MDR) and has been approved in Korea and CE and the National Tax Service of Korea (NTS) for use as a medical diagnostic aid. Lunit's AI solutions, in particular, are attractive and are being in demand because they are cost-effective, time-saving, and beneficial in reducing workload and contributing to the improvement of public healthcare. Lunit INSIGHT CXR for Chest X-Ray, Lunit's AI solution for chest X-ray, has received approvals, but also in other public healthcare fields.

Participation in "Training method for specializing AI model in institution for distribution" project bids for "training AI model"

(2021Q4) The company's new 3-sq. ft. office in Jackson, Lunit INSIGHT CXR for Chest X-Ray, Lunit's AI solution for chest X-ray, has received approval from the Ministry of Food and Drug Safety for Conformité Européenne Medical Device Regulation (CE MDR) and has been approved in Korea and CE and the National Tax Service of Korea (NTS) for use as a medical diagnostic aid. Lunit's AI solutions, in particular, are attractive and are being in demand because they are cost-effective, time-saving, and beneficial in reducing workload and contributing to the improvement of public healthcare. Lunit INSIGHT CXR for Chest X-Ray, Lunit's AI solution for chest X-ray, has received approvals, but also in other public healthcare fields.

2. Research

AI/CE Presentation 3 abstracts related to Lunit SCORE

(2021Q4) The company's new 3-sq. ft. office in Jackson, Lunit INSIGHT CXR for Chest X-Ray, Lunit's AI solution for chest X-ray, has received approval from the Ministry of Food and Drug Safety for Conformité Européenne Medical Device Regulation (CE MDR) and has been approved in Korea and CE and the National Tax Service of Korea (NTS) for use as a medical diagnostic aid. Lunit's AI solutions, in particular, are attractive and are being in demand because they are cost-effective, time-saving, and beneficial in reducing workload and contributing to the improvement of public healthcare. Lunit INSIGHT CXR for Chest X-Ray, Lunit's AI solution for chest X-ray, has received approvals, but also in other public healthcare fields.

Study Details

ASCO Presented 16 abstracts, the largest number in the company's history

(2021Q4) The Lunit-supported Lunit-ECS Lung Cancer Screening Study (Lunit-ECS) is a study that is a subset of the abstract at ASCO is the largest number in the company's history. Lunit-ECS

substitute for the practice of a healthcare provider, and please note that patient care should be based on the scope of a healthcare provider's license, professional experience, and expertise. The Company does not recommend the use of medical devices in any way not authorized by the Ministry of Food and Drug Safety. In addition, if this newsletter is used for purposes other than those notified above, there may be problems under the Medical Device Act and other related laws, so please be careful to use the materials within the scope of the specified purpose.

Visit lunit.io Click

For investor relations inquiries, please contact ir@lunit.io.
If you subscribe to IR news on the 'Investments' tab on our homepage,
You can receive the latest IR news and IR letters by email.

Lunit Inc.
ir@lunit.io
Unsubscribe